<?xml version="1.0" encoding="UTF-8"?>
<HtmlDoc>
    <meta>
        <prop name="uid">https://www.ncbi.nlm.nih.gov/pubmed/28719608?report=xml&amp;format=text</prop>
        <prop name="date">2017-09-29</prop>
        <prop name="copyright">Converted by Semantic Hub (c) 2016</prop>
        <prop name="version">1.0</prop>
        <prop name="query">(potent AND inhibitor AND cancer) : 2015-2017</prop>
    </meta>
    <BODY>
        <ITEM>
            <ITEM_LINK>https://www.ncbi.nlm.nih.gov/pubmed/28719608?report=xml&amp;format=text</ITEM_LINK>
            <ITEM_BODY>
                <MedlineCitation Owner="NLM" Status="MEDLINE">
                    <PMID Version="1">28719608</PMID>
                    <DateCreated>
                        <Year>2017</Year>
                        <Month>07</Month>
                        <Day>18</Day>
                    </DateCreated>
                    <DateCompleted>
                        <Year>2017</Year>
                        <Month>09</Month>
                        <Day>27</Day>
                    </DateCompleted>
                    <DateRevised>
                        <Year>2017</Year>
                        <Month>09</Month>
                        <Day>27</Day>
                    </DateRevised>
                    <Article PubModel="Electronic-eCollection">
                        <Journal>
                            <ISSN IssnType="Electronic">1932-6203</ISSN>
                            <JournalIssue CitedMedium="Internet">
                                <Volume>12</Volume>
                                <Issue>7</Issue>
                                <PubDate>
                                    <Year>2017</Year>
                                </PubDate>
                            </JournalIssue>
                            <Title>PloS one</Title>
                            <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
                        </Journal>
                        <ArticleTitle>
                            Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
                        </ArticleTitle>
                        <Pagination>
                            <MedlinePgn>e0179558</MedlinePgn>
                        </Pagination>
                        <ELocationID ValidYN="Y" EIdType="doi">10.1371/journal.pone.0179558</ELocationID>
                        <Abstract>
                            <AbstractText>
                                Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved greatly. However, ~30-40% of patients develop resistance to imatinib therapy. Although most resistance is caused by mutations in the BCR-ABL kinase domain, 50-85% of these patients develop resistance in the absence of new mutations. In these cases, targeting other pathways may be needed to regain clinical response. Using label-free Raman spectromicroscopy, we evaluated a number of leukemia cell lines and discovered an aberrant accumulation of cholesteryl ester (CE) in CML, which was found to be a result of BCR-ABL kinase activity. CE accumulation in CML was found to be a cancer-specific phenomenon as untransformed cells did not accumulate CE. Blocking cholesterol esterification with avasimibe, a potent inhibitor of acyl-CoA cholesterol acyltransferase 1 (ACAT-1), significantly suppressed CML cell proliferation in Ba/F3 cells with the BCR-ABLT315I mutation and in K562 cells rendered imatinib resistant without mutations in the BCR-ABL kinase domain (K562R cells). Furthermore, the combination of avasimibe and imatinib caused a profound synergistic inhibition of cell proliferation in K562R cells, but not in Ba/F3T315I. This synergistic effect was confirmed in a K562R xenograft mouse model. Analysis of primary cells from a BCR-ABL mutation-independent imatinib resistant patient by mass cytometry suggested that the synergy may be due to downregulation of the MAPK pathway by avasimibe, which sensitized the CML cells to imatinib treatment. Collectively, these data demonstrate a novel strategy for overcoming BCR-ABL mutation-independent TKI resistance in CML.
                            </AbstractText>
                        </Abstract>
                        <AuthorList CompleteYN="Y">
                            <Author ValidYN="Y">
                                <LastName>Bandyopadhyay</LastName>
                                <ForeName>Shovik</ForeName>
                                <Initials>S</Initials>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Department of Biological Sciences, Purdue University, West Lafayette, Indiana, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                            </Author>
                            <Author ValidYN="Y">
                                <LastName>Li</LastName>
                                <ForeName>Junjie</ForeName>
                                <Initials>J</Initials>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                            </Author>
                            <Author ValidYN="Y">
                                <LastName>Traer</LastName>
                                <ForeName>Elie</ForeName>
                                <Initials>E</Initials>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Knight Cancer Institute, Oregon Health &amp; Science University, Portland, Oregon, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                            </Author>
                            <Author ValidYN="Y">
                                <LastName>Tyner</LastName>
                                <ForeName>Jeffrey W</ForeName>
                                <Initials>JW</Initials>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Knight Cancer Institute, Oregon Health &amp; Science University, Portland, Oregon, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Department of Cell, Developmental &amp; Cancer Biology, Oregon Health &amp; Science University, Portland, Oregon, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                            </Author>
                            <Author ValidYN="Y">
                                <LastName>Zhou</LastName>
                                <ForeName>Amy</ForeName>
                                <Initials>A</Initials>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Division of Hematology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                            </Author>
                            <Author ValidYN="Y">
                                <LastName>Oh</LastName>
                                <ForeName>Stephen T</ForeName>
                                <Initials>ST</Initials>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Division of Hematology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                            </Author>
                            <Author ValidYN="Y">
                                <LastName>Cheng</LastName>
                                <ForeName>Ji-Xin</ForeName>
                                <Initials>JX</Initials>
                                <Identifier Source="ORCID">http://orcid.org/0000-0002-5607-6683</Identifier>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                                <AffiliationInfo>
                                    <Affiliation>
                                        Center for Cancer Research, Purdue University, West Lafayette, Indiana, United States of America.
                                    </Affiliation>
                                </AffiliationInfo>
                            </Author>
                        </AuthorList>
                        <Language>eng</Language>
                        <GrantList CompleteYN="Y">
                            <Grant>
                                <GrantID>K08 HL106576</GrantID>
                                <Acronym>HL</Acronym>
                                <Agency>NHLBI NIH HHS</Agency>
                                <Country>United States</Country>
                            </Grant>
                            <Grant>
                                <GrantID>P01 CA101937</GrantID>
                                <Acronym>CA</Acronym>
                                <Agency>NCI NIH HHS</Agency>
                                <Country>United States</Country>
                            </Grant>
                            <Grant>
                                <GrantID>P30 CA091842</GrantID>
                                <Acronym>CA</Acronym>
                                <Agency>NCI NIH HHS</Agency>
                                <Country>United States</Country>
                            </Grant>
                        </GrantList>
                        <PublicationTypeList>
                            <PublicationType UI="D016428">Journal Article</PublicationType>
                        </PublicationTypeList>
                        <ArticleDate DateType="Electronic">
                            <Year>2017</Year>
                            <Month>07</Month>
                            <Day>18</Day>
                        </ArticleDate>
                    </Article>
                    <MedlineJournalInfo>
                        <Country>United States</Country>
                        <MedlineTA>PLoS One</MedlineTA>
                        <NlmUniqueID>101285081</NlmUniqueID>
                        <ISSNLinking>1932-6203</ISSNLinking>
                    </MedlineJournalInfo>
                    <ChemicalList>
                        <Chemical>
                            <RegistryNumber>0</RegistryNumber>
                            <NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
                        </Chemical>
                        <Chemical>
                            <RegistryNumber>0</RegistryNumber>
                            <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
                        </Chemical>
                        <Chemical>
                            <RegistryNumber>0</RegistryNumber>
                            <NameOfSubstance UI="D013451">Sulfonic Acids</NameOfSubstance>
                        </Chemical>
                        <Chemical>
                            <RegistryNumber>28LQ20T5RC</RegistryNumber>
                            <NameOfSubstance UI="C423185">avasimibe</NameOfSubstance>
                        </Chemical>
                        <Chemical>
                            <RegistryNumber>8A1O1M485B</RegistryNumber>
                            <NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance>
                        </Chemical>
                        <Chemical>
                            <RegistryNumber>97C5T2UQ7J</RegistryNumber>
                            <NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
                        </Chemical>
                        <Chemical>
                            <RegistryNumber>EC 2.7.10.2</RegistryNumber>
                            <NameOfSubstance UI="D016044">Fusion Proteins, bcr-abl</NameOfSubstance>
                        </Chemical>
                    </ChemicalList>
                    <CitationSubset>IM</CitationSubset>
                    <CommentsCorrectionsList>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Cancer Res. 2002 Dec 15;62(24):7149-53</RefSource>
                            <PMID Version="1">12499247</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Cell Prolif. 2011 Aug;44(4):360-71</RefSource>
                            <PMID Version="1">21645151</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>PLoS One. 2009 Oct 13;4(10 ):e7439</RefSource>
                            <PMID Version="1">19823681</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Sci Transl Med. 2014 Sep 3;6(252):252ra121</RefSource>
                            <PMID Version="1">25186176</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Cancer Biol Ther. 2010 Jun 15;9(12):1025-32</RefSource>
                            <PMID Version="1">20404512</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Hematology Am Soc Hematol Educ Program. 2009;:461-76</RefSource>
                            <PMID Version="1">20008232</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Breast Cancer Res Treat. 2010 Aug;122(3):661-70</RefSource>
                            <PMID Version="1">19851860</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Sci Rep. 2014 Oct 29;4:6807</RefSource>
                            <PMID Version="1">25351207</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Oncogene. 2016 Dec 15;35(50):6378-6388</RefSource>
                            <PMID Version="1">27132508</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Circulation. 2004 Nov 23;110(21):3372-7</RefSource>
                            <PMID Version="1">15533865</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>FEBS J. 2012 Aug;279(15):2610-23</RefSource>
                            <PMID Version="1">22621751</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Nat Biotechnol. 2013 Jun;31(6):545-52</RefSource>
                            <PMID Version="1">23685480</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Br J Pharmacol. 2001 Nov;134(5):1055-65</RefSource>
                            <PMID Version="1">11682454</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Eur J Cancer. 2013 Oct;49(15):3242-6</RefSource>
                            <PMID Version="1">23876833</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Cell Metab. 2013 Aug 6;18(2):153-61</RefSource>
                            <PMID Version="1">23791484</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Science. 2011 May 6;332(6030):687-96</RefSource>
                            <PMID Version="1">21551058</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Cancer Res. 2010 Jan 15;70(2):440-6</RefSource>
                            <PMID Version="1">20068163</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>J Phys Chem B. 2009 May 28;113(21):7681-6</RefSource>
                            <PMID Version="1">19422201</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Cell Metab. 2014 Mar 4;19(3):393-406</RefSource>
                            <PMID Version="1">24606897</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Nat Rev Cancer. 2007 Oct;7(10):763-77</RefSource>
                            <PMID Version="1">17882277</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Ther Adv Hematol. 2014 Aug;5(4):107-20</RefSource>
                            <PMID Version="1">25360237</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Blood. 2014 Mar 6;123(10):1516-24</RefSource>
                            <PMID Version="1">24408322</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Leukemia. 2009 Jun;23(6):1054-61</RefSource>
                            <PMID Version="1">19282833</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>Curr Med Res Opin. 2010 Feb;26(2):307-17</RefSource>
                            <PMID Version="1">19961284</PMID>
                        </CommentsCorrections>
                        <CommentsCorrections RefType="Cites">
                            <RefSource>ACS Nano. 2015 Mar 24;9(3):2420-32</RefSource>
                            <PMID Version="1">25662106</PMID>
                        </CommentsCorrections>
                    </CommentsCorrectionsList>
                    <MeshHeadingList>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D000085">Acetates</DescriptorName>
                            <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                            <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
                            <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D002784">Cholesterol</DescriptorName>
                            <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
                            <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
                            <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                            <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D004951">Esterification</DescriptorName>
                            <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D016044">Fusion Proteins, bcr-abl</DescriptorName>
                            <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D000068877">Imatinib Mesylate</DescriptorName>
                            <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                            <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D020014">K562 Cells</DescriptorName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D015464">
                                Leukemia, Myelogenous, Chronic, BCR-ABL Positive
                            </DescriptorName>
                            <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                            <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                            <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                            <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
                            <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
                            <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                            <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D013451">Sulfonic Acids</DescriptorName>
                            <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                        </MeshHeading>
                        <MeshHeading>
                            <DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
                        </MeshHeading>
                    </MeshHeadingList>
                </MedlineCitation>
                <PubmedData>
                    <History>
                        <PubMedPubDate PubStatus="received">
                            <Year>2017</Year>
                            <Month>01</Month>
                            <Day>23</Day>
                        </PubMedPubDate>
                        <PubMedPubDate PubStatus="accepted">
                            <Year>2017</Year>
                            <Month>05</Month>
                            <Day>30</Day>
                        </PubMedPubDate>
                        <PubMedPubDate PubStatus="entrez">
                            <Year>2017</Year>
                            <Month>7</Month>
                            <Day>19</Day>
                            <Hour>6</Hour>
                            <Minute>0</Minute>
                        </PubMedPubDate>
                        <PubMedPubDate PubStatus="pubmed">
                            <Year>2017</Year>
                            <Month>7</Month>
                            <Day>19</Day>
                            <Hour>6</Hour>
                            <Minute>0</Minute>
                        </PubMedPubDate>
                        <PubMedPubDate PubStatus="medline">
                            <Year>2017</Year>
                            <Month>9</Month>
                            <Day>28</Day>
                            <Hour>6</Hour>
                            <Minute>0</Minute>
                        </PubMedPubDate>
                    </History>
                    <PublicationStatus>epublish</PublicationStatus>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28719608</ArticleId>
                        <ArticleId IdType="doi">10.1371/journal.pone.0179558</ArticleId>
                        <ArticleId IdType="pii">PONE-D-17-03053</ArticleId>
                        <ArticleId IdType="pmc">PMC5515395</ArticleId>
                    </ArticleIdList>
                </PubmedData>
            </ITEM_BODY>
        </ITEM>
    </BODY>
</HtmlDoc>